At a Glance
Quickcomparison
Dose Range
CJC-1295 with DAC
1000–2000 mcg
CJC-1295 (No DAC)
100–300 mcg
Frequency
Twice weekly
Once daily
Administration
Subcutaneous injection
Cycle Length
8-12 weeks
Onset Speed
Moderate (1-2 weeks)
Evidence Level
Moderate human trials (Phase 1-2)
Efficacy
Benefitratings
GH Elevation
Convenience
Recovery Support
GH Stimulation
Sleep Quality
Technical Data
Compoundspecifications
Molecular Formula
C165H269N47O46
Molecular Weight
3647.28 g/mol
Half-Life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS Number
863288-34-0
C152H252N44O42
3367.9 g/mol
30 minutes to 2 hours
Protocols
Dosingtiers
starting
1 mg (1000 mcg)
Once weekly
2-4 weeks
A starting dose used in practice. The DAC version is long-acting (about a 6-8 day half-life), so weekly dosing keeps growth hormone and IGF-1 raised. In the Phase 1 trial a single dose raised GH for 6+ days and IGF-1 for up to 11 days. [2]
standard
2 mg (2000 mcg)
Once weekly (or split twice weekly)
The common maintenance dose, roughly in line with the 30-60 mcg/kg weekly range studied in the Phase 1 trial. [1][2]
advanced
2 mg per dose
A higher total weekly amount split into two doses, used by experienced users; near the top of the 30-60 mcg/kg weekly range from the clinical study. [2]
100 mcg
Once daily, 30 minutes before bed
A common starting dose used in research practice. Because the no-DAC form is short-acting (about 30 minute half-life), it is injected on an empty stomach for the best growth-hormone pulse. [1]
100 mcg per dose
1-2 times daily
The typical maintenance dose used in practice, often given before bed and/or after fasted exercise. Frequently paired with a GH-releasing peptide. [1]
2-3 times daily
A higher-frequency plan used by experienced users to mimic natural GH pulses across the day, each dose taken fasted. [1]
Applications
Bestsuited for
Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.
Natural Growth Hormone Optimization
Perfect for those wanting to boost their body's own GH production rather than using synthetic growth hormone. Mimics the natural pulsatile release pattern your pituitary uses.
Workout Recovery and Muscle Building
Athletes and fitness enthusiasts use it to accelerate recovery between training sessions, support lean muscle development, and reduce body fat over time.
Sleep Quality Enhancement
Because GH is naturally released during deep sleep, many users report dramatically improved sleep quality with more vivid dreams and feeling more refreshed upon waking.
Anti-Aging and Vitality
As GH levels decline with age, CJC-1295 helps restore more youthful hormone patterns, potentially improving skin quality, energy levels, and overall well-being.
Synergistic Peptide Stacking
Designed to work hand-in-hand with GHRPs like Ipamorelin. When combined, these peptides amplify each other's effects for significantly greater GH release than either alone.
Safety Profile
Sideeffects
Common
Injection site reactions
Water retention
Flushing
Tingling sensation
Uncommon
Headaches
Fatigue or lethargy
Joint discomfort
Serious
Carpal tunnel symptoms
Blood glucose elevation
Flushing or warmth
Increased appetite
Tingling or numbness
Headache
Allergic reaction
Research Status
Safety& evidence
FDA Status
Research compound
Safety Overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.
Contraindications
xActive cancer or history of malignancy
xPregnancy or breastfeeding
xPituitary tumors or disorders
xDiabetic retinopathy
xUncontrolled diabetes
CJC-1295 without DAC has been studied in Phase 1-2 human clinical trials with a favorable safety profile. The most common side effects are mild and include injection site reactions and temporary flushing. Because it stimulates natural GH release rather than providing exogenous GH, it maintains the body's feedback mechanisms.
xActive cancer or history of cancer
xHypersensitivity to GHRH analogs
Decision Guide
Which isright for you?
Choose CJC-1295 with DAC if...
Boosting natural growth hormone production
Building lean muscle mass
Improving body composition
Anti-aging and longevity
Choose CJC-1295 (No DAC) if...
Increasing natural growth hormone levels
Improving sleep quality
Enhancing workout recovery